Takeda Pharmaceutical Co Ltd
TAK14.915USD
+0.085+0.57%
收盤 12/19, 16:00（美東）報價延遲15分鐘
47.12B總市值
209.33本益比TTM
關於 Takeda Pharmaceutical Co Ltd 公司
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
Takeda Pharmaceutical Co Ltd簡介
公司代碼TAK
公司名稱Takeda Pharmaceutical Co Ltd
上市日期Jun 21, 2085
CEOWeber (Christophe)
員工數量47455
證券類型Depository Receipt
年結日Jun 21
公司地址4F
城市CHUO-KU
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家Japan
郵編103-8668
電話81332782111
網址https://www.takeda.com/
公司代碼TAK
上市日期Jun 21, 2085
CEOWeber (Christophe)
Takeda Pharmaceutical Co Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
Mr. Koji Hatsukawa
Mr. Koji Hatsukawa
Independent Director
Independent Director
--
--
Mr. Milano Furuta
Mr. Milano Furuta
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. Masami Iijima
Mr. Masami Iijima
Chairman of Board of Directors, Independent Director
Chairman of Board of Directors, Independent Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Gastrointestinal diseases
339.30B
30.66%
Plasma derivatives
260.90B
23.57%
Rare diseases
196.40B
17.75%
Oncology
138.80B
12.54%
Neuroscience
108.60B
9.81%
其他
62.70B
5.67%
地區USD
名稱
營收
佔比
United States
546.70B
49.40%
Europe And Canada (Country)
262.30B
23.70%
Japan
108.00B
9.76%
Latin America
57.60B
5.20%
China (Country)
43.20B
3.90%
其他
88.90B
8.03%
業務
地區
業務USD
名稱
營收
佔比
Gastrointestinal diseases
339.30B
30.66%
Plasma derivatives
260.90B
23.57%
Rare diseases
196.40B
17.75%
Oncology
138.80B
12.54%
Neuroscience
108.60B
9.81%
其他
62.70B
5.67%
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.19%
UBS Financial Services, Inc.
0.19%
Fidelity Management & Research Company LLC
0.13%
Brandes Investment Partners, L.P.
0.12%
其他
98.94%
持股股東
持股股東
佔比
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.19%
UBS Financial Services, Inc.
0.19%
Fidelity Management & Research Company LLC
0.13%
Brandes Investment Partners, L.P.
0.12%
其他
98.94%
股東類型
持股股東
佔比
Investment Advisor
1.85%
Hedge Fund
0.32%
Investment Advisor/Hedge Fund
0.31%
Research Firm
0.21%
Family Office
0.01%
Family Office
0.01%
Family Office
0.01%
其他
97.27%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
606
78.67M
2.49%
-1.76M
2025Q2
594
72.78M
2.30%
-6.62M
2025Q1
603
72.05M
2.31%
-7.59M
2024Q4
595
73.56M
2.33%
-9.88M
2024Q3
583
77.60M
2.45%
-3.33M
2024Q2
581
73.43M
2.34%
-14.54M
2024Q1
593
78.98M
2.52%
-11.62M
2023Q4
609
83.80M
2.67%
-18.91M
2023Q3
621
81.24M
2.59%
-37.59M
2023Q2
617
84.64M
2.72%
-34.14M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Capital Research Global Investors
13.30M
0.42%
+94.57K
+0.72%
Jun 30, 2025
Parametric Portfolio Associates LLC
5.97M
0.19%
+676.71K
+12.78%
Jun 30, 2025
UBS Financial Services, Inc.
3.98M
0.13%
+2.28M
+133.74%
Jun 30, 2025
Fidelity Management & Research Company LLC
4.08M
0.13%
+275.19K
+7.23%
Jun 30, 2025
Brandes Investment Partners, L.P.
3.71M
0.12%
+208.14K
+5.94%
Jun 30, 2025
Renaissance Technologies LLC
3.30M
0.1%
+141.50K
+4.48%
Jun 30, 2025
Goldman Sachs Asset Management, L.P.
2.85M
0.09%
-44.41K
-1.53%
Jun 30, 2025
Aperio Group, LLC
3.20M
0.1%
+574.34K
+21.83%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
1.22M
0.04%
-181.77K
-12.98%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
VanEck Pharmaceutical ETF
5.05%
SGI Enhanced Global Income ETF
0.76%
Adasina Social Justice All Cap Global ETF
0.49%
First Trust Value Line Dividend Index Fund
0.38%
ActivePassive International Equity ETF
0.3%
Avantis Responsible International Equity ETF
0.09%
Avantis International Equity ETF
0.05%
Roundhill GLP-1 & Weight Loss ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
Invesco Zacks Multi-Asset Income ETF
0%
查看更多
VanEck Pharmaceutical ETF
佔比5.05%
SGI Enhanced Global Income ETF
佔比0.76%
Adasina Social Justice All Cap Global ETF
佔比0.49%
First Trust Value Line Dividend Index Fund
佔比0.38%
ActivePassive International Equity ETF
佔比0.3%
Avantis Responsible International Equity ETF
佔比0.09%
Avantis International Equity ETF
佔比0.05%
Roundhill GLP-1 & Weight Loss ETF
佔比0%
DFA Dimensional International Core Equity 2 ETF
佔比0%
Invesco Zacks Multi-Asset Income ETF
佔比0%
分紅派息
近5年累計派現
1.44T
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Sep 08, 2025
TAK.NB Final Cash Dividend of gross USD 0.322144 paid on Dec 11, 2025 going ex on Sep 30, 2025
Sep 30, 2025
Dec 11, 2025
Sep 30, 2025
Mar 04, 2025
TAK.NB Approximate interim Cash Dividend of gross USD 0.33901 paid on Jul 07, 2025 going ex on Mar 31, 2025
Mar 31, 2025
Jul 07, 2025
Mar 31, 2025
Sep 12, 2024
TAK.NB Final Cash Dividend of gross USD 0.326079 paid on Dec 12, 2024 going ex on Sep 30, 2024
Sep 30, 2024
Dec 12, 2024
Sep 30, 2024
Mar 14, 2024
TAK.NB Interim Cash Dividend of gross USD 0.292214 paid on Jul 08, 2024 going ex on Mar 27, 2024
Mar 28, 2024
Jul 08, 2024
Mar 27, 2024
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Takeda Pharmaceutical Co Ltd的前五大股東是誰？
Takeda Pharmaceutical Co Ltd的前五大股東如下：
Capital Research Global Investors持有股份：13.30M佔總股份比例：0.42%。
Parametric Portfolio Associates LLC持有股份：5.97M佔總股份比例：0.19%。
UBS Financial Services, Inc.持有股份：3.98M佔總股份比例：0.13%。
Fidelity Management & Research Company LLC持有股份：4.08M佔總股份比例：0.13%。
Brandes Investment Partners, L.P.持有股份：3.71M佔總股份比例：0.12%。
Capital Research Global Investors持有股份：13.30M佔總股份比例：0.42%。
Parametric Portfolio Associates LLC持有股份：5.97M佔總股份比例：0.19%。
UBS Financial Services, Inc.持有股份：3.98M佔總股份比例：0.13%。
Fidelity Management & Research Company LLC持有股份：4.08M佔總股份比例：0.13%。
Brandes Investment Partners, L.P.持有股份：3.71M佔總股份比例：0.12%。
Takeda Pharmaceutical Co Ltd的前三大股東類型是什麼？
Takeda Pharmaceutical Co Ltd 的前三大股東類型分別是：
Capital Research Global Investors
Parametric Portfolio Associates LLC
UBS Financial Services, Inc.
Capital Research Global Investors
Parametric Portfolio Associates LLC
UBS Financial Services, Inc.
有多少機構持有Takeda Pharmaceutical Co Ltd(TAK)的股份？
截至2025Q3，共有606家機構持有Takeda Pharmaceutical Co Ltd的股份，合計持有的股份價值約為78.67M，占公司總股份的2.49% 。與2025Q2相比，機構持股有所增加，增幅為0.19%。
哪個業務部門對Takeda Pharmaceutical Co Ltd的收入貢獻最大？
在FY2026Q1，Gastrointestinal diseases業務部門對Takeda Pharmaceutical Co Ltd的收入貢獻最大，創收339.30B，占總收入的30.66% 。
